2020
DOI: 10.1186/s12872-020-01466-5
|View full text |Cite
|
Sign up to set email alerts
|

Assessing the risk of angiotensin receptor blockers on major cardiovascular events: a systematic review and meta-analysis of randomized controlled trials

Abstract: Background: Angiotensin receptor blockers (ARBs) are commonly used as a treatment for many cardiovascular diseases, but their safety has been called into question. The VALUE trial found an increased risk of myocardial infarction in participants receiving ARBs compared to other antihypertensive. The aim of the meta-analysis was to synthetize the available evidence of randomised controlled trials (RCTs) and elucidate if ARBs increase the risk of cardiovascular events. Methods: A comprehensive search was conducte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 65 publications
0
4
0
Order By: Relevance
“…28 A meta-analysis study revealed that ARBs are safe drugs and do not increase the risk of death, myocardial infarction, and stroke. 29 The main goal of hypertension treatment is to control the target blood pressure. Recommended firstline therapy includes thiazide-type diuretics, calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor blockers (ARBs).…”
Section: Discussionmentioning
confidence: 99%
“…28 A meta-analysis study revealed that ARBs are safe drugs and do not increase the risk of death, myocardial infarction, and stroke. 29 The main goal of hypertension treatment is to control the target blood pressure. Recommended firstline therapy includes thiazide-type diuretics, calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor blockers (ARBs).…”
Section: Discussionmentioning
confidence: 99%
“… 5–10 It might reflect the well-recognised effectiveness of antiplatelet agents or statin in the early post-PCI period, 25 and relatively less recognised or limited use of beta-blocker or ACEi/ARB. 26 , 27 Taken together, patients with unfavourable characteristics might have clinical reasons for discontinuing GDMT such as low blood pressure, bradycardia, impaired renal function, drug intolerance, or non-cardiovascular major illness. In such cases, use of all GDMT medication might be limited.…”
Section: Discussionmentioning
confidence: 99%
“…Mimo to stosowanie sartanów w odniesieniu do placebo może w niewielkim stopniu obniżać ryzyko udaru mózgu (RR = 0,91; 95% CI: 0,85--0,98), co wykazano w metaanalizie 45 randomizowanych badań klinicznych, którą przeprowadzili Wanas i wsp. Co interesujące, stosowanie sartanów może być związane z większym zmniejszeniem ryzyka udaru mózgu w takich podgrupach chorych, jak osoby niepalące papierosów oraz osoby z zaburzeniami lipidowymi [80]. W metaanalizie 26 randomizowanych badań klinicznych, którą przeprowadzili Savarese i wsp., stwierdzono, że sartany obniżały ryzyko wystąpienia udaru mózgu u chorych z wysokim ryzykiem sercowo-naczyniowym, ale bez niewydolności serca (OR = 0,9; 95% CI: 0,8-0,9) [81].…”
Section: Wpływ Na Ryzyko Wystąpienia Hipotonii Ortostatycznejunclassified